Pfizer CEO Profits After COVID Vaccine Announcement

Eyebrows raised when Pfizer CEO sold some of his holdings in the company to the tune of $5.6 million. The prescheduled sale came at the perfect time, when the company publicly announced promising results from early COVID vaccine trials. CNBC reports that Bourla’s base salary was $1.65 million in April. After his most recent sale of shares, he still owns nine times his salary in shares, approximately $15 million.

MarketScale Radio hosts Daniel Litwin and Tyler Kern dissect the news. Litwin considers the serendipity of the sale timed with the public announcement. Kern and Litwin consider the thought of one person profiting tremendously off of a public good like a life-saving vaccine, and in the end, Kern points out, any one takeaway depends on how one feels about capitalism’s economic structures and incentives.

KEY POINTS:

  • Pfizer CEO Albert Bourla sells $5.6 million worth of stock just as it jumps 15%.
  • The sale was pre-scheduled, but opportunely timed with the public announcement of a promising vaccine.
  • Other medical executives at Moderna also are cashing in on spiking stocks while vaccines inch toward approval.

For the latest news, videos, and podcasts in the Healthcare Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

finance
Dr. Silver Kung’s Path From $10 Million in Debt to a Multibillion-Dollar Finance Career
May 21, 2026

Global finance is being tested by forces that no balance sheet can fully predict: unstable supply chains, geopolitical shocks, tighter credit conditions and the accelerating rise of AI. In trade finance especially, success depends on more than capital; it requires judgment, discipline and the ability to see risk before it becomes disruption. As automation…

Read More
specialty pharmacy
At the Center of Care: How Specialty Pharmacy Aligns Patients, Providers, and Payers
May 21, 2026

As healthcare costs continue to rise, more patients are finding themselves navigating not just illness, but the growing complexity of paying for treatment. Specialty pharmacy sits right at the center of that challenge—often out of sight, but increasingly essential to how modern care actually works. These high-cost, high-touch therapies now make up more than…

Read More
Language development
Just Thinking… About How Multilingualism and Language Development Belong at the Center of Student Learning
May 20, 2026

For millions of students in America, learning English is only one part of a much larger academic story. A 2024 GAO report found that English learners in U.S. public schools grew from 4.5 million to 5 million students between fall 2010 and fall 2020, and that they speak more than 400 languages. That diversity…

Read More
AI Infrastructure
Simplifying AI Infrastructure: From Data Center to Deployment (Part 1)
May 19, 2026

In this episode of the Flawless Execution podcast, Jeff Hudgins, VP of Global Services at UNICOM Engineering, breaks down the real-world challenges of deploying AI infrastructure at scale. As AI moves from one-off builds to repeatable global deployments, OEMs, ISVs, and enterprises face increasing complexity across design, integration, cooling, logistics, and installation. Jeff discusses how…

Read More